微生物异质性介导的治疗逃避和工程活生物治疗产品的潜力
Eli G Cytrynbaum1, Megan N McClean2
1Department of Cellular and Molecular Biology, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
微生物异质性为治疗真菌感染带来了挑战. 工程活生物治疗产品 (eLBPs) 提供了一种有前途的新策略,用于向耐药和毒性真菌,如Candida albicans.
科学领域:
- 微生物学 微生物学
- 菌类学 菌类学是指菌类学.
- 生物技术是生物技术.
背景情况:
- 微生物种群表现出遗传和非遗传异质性,使临床治疗复杂化.
- 真菌病原体,特别是Candida物种,由于疾病发病率和抗真菌耐药性的增加,越来越多的挑战.
- 由于真菌和人类真核细胞之间的相似性,针对致病菌很困难.
研究的目的:
- 审查微生物异质性对抗真菌治疗策略的影响.
- 探索工程活生物治疗产品 (eLBPs) 治疗真菌感染的潜力.
- 评估eLBP对抗异构真菌种群的现状和未来前景.
主要方法:
- 病原性真菌中的微生物异质性的文献综述.
- 对导致抗真菌耐药性和免疫逃避的遗传和非遗传因素的分析.
- 工程活生物疗法产品 (eLBPs) 作为治疗方式的评估.
主要成果:
- 微生物异质性提供了生存优势,包括增强的免疫逃避和抗菌素耐药性.
- 目前的抗真菌策略往往不足以对抗异构的真菌种群.
- 工程活生物治疗产品 (eLBPs) 显示出针对真菌感染的向,局部和持续治疗的潜力.
结论:
- 了解微生物异质性对于开发有效的抗真菌疗法至关重要.
- 工程活生物治疗产品 (eLBPs) 代表了一种新且有前途的方法来应对异构的真菌病原体带来的挑战.
- 需要进一步的研究和开发,以实现eLBPs在真菌感染的临床环境中的全部潜力.
更多相关视频
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
09:09High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
相关概念视频
Microorganisms in Medicine and Therapeutics
Biological Methods for Microbial Control
Drug Products: Biologics, Biosimilars and Interchangeables
Development of Antibiotic Resistance
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Gene Regulation in Microbial Communities: Quorum Sensing
